← Leaderboards
Gopa Iyer
Sloan-Kettering Inst Can Research
$1,323,037
Attributed
$3,677,125
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,677,125 · 3
By mechanism
T32$1,979,709 · 1
R01$1,697,416 · 2
Top collaborators
- Alexander Drilon4 shared
- David B. Solit3 shared
- Omar Abdel-Wahab2 shared
- Dean F. Bajorin2 shared
- Randy Yeh2 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- David B. Solit$21,393,031
- Sarat Chandarlapaty$10,852,142
- Elisa De Stanchina$4,011,743
- Alexander Drilon$4,847,187
- Hikmat Al-Ahmadie$4,559,862
Others in their field
Other Rising Stars on “Malignant Neoplasms”
- David Annett · Information Management Services, Inc.$35,571,865
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Jon White · Midwest Research Institute$17,594,074
- Carolina Porras · Fundacion Inciensa$10,814,023
- Alanna Maguire · Mayo Clinic Rochester$9,942,431
- Hill Georgette · Integrated Laboratory Systems, Llc$8,700,000
Research focus
Malignant NeoplasmsTraining ProgramsSamplingOrganoidsProspectiveResponseKinase InhibitorDesignMutationMutational StatusFibroblast Growth Factor ReceptorsAnti-Pd-1/Pd-L1Cancer TypeResistanceAntibody-Drug ConjugatesFutureClinically SignificantGenomicsDisease ProgressionMutateCohortDna Sequence AlterationBladderPathogenesis
Grant awards (7)
The Role of EP300 Mutations in Bladder Cancer Pathogenesis and Drug Response$583,973
R01 · FY2025 · CA
HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma$556,762
R01 · FY2025 · CA · contact PI
Investigational Cancer Therapeutics Training Program (ICTTP)$59,553
T32 · FY2025 · CA
Investigational Cancer Therapeutics Training Program (ICTTP)$584,360
T32 · FY2024 · CA
HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma$556,681
R01 · FY2024 · CA · contact PI
Investigational Cancer Therapeutics Training Program$759,367
T32 · FY2023 · CA
Investigational Cancer Therapeutics Training Program$576,429
T32 · FY2022 · CA